EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSMMDG00005004658
Gene Symbol: MAP3K12
1 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSMMDG00005007583
Gene Symbol: MAP3K12
1 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSMMDG00005009367
Gene Symbol: MAP3K13
1 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSMMDG00005017836
Gene Symbol: MAP3K5
1 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSMMDG00005023768
Gene Symbol: MAP3K8
3 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSMMDG00005019480
Gene Symbol: MAP3K9
1 Cross references
193 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSMMDG00005005227
Gene Symbol: MGLL
3 Cross references
208 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSMMDG00005015212
Gene Symbol: MLNR
1 Cross references
174 Possible Orthologues:

Muscarinic Acetylcholine Receptor M2-Like

Ensembl ID : ENSMMDG00005013630
Gene Symbol: LOC115360196
2 Cross references
185 Possible Orthologues:

Muscarinic Acetylcholine Receptor M5-Like

Ensembl ID : ENSMMDG00005012327
Gene Symbol: LOC115380711
3 Cross references
195 Possible Orthologues:

Muscarinic Acetylcholine Receptor M5-Like

Ensembl ID : ENSMMDG00005015013
Gene Symbol: LOC115355680
3 Cross references
189 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSMMDG00005010154
Gene Symbol: NPR3
1 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).